On Mother’s Day 2020, an ordinary holiday in Colorado became a missing-person clock. Suzanne Morphew was reported missing on May 10. The first account pointed to a bike ride while Barry Morphew was away for work. But investigators could not complete that story. A bike, a route, a window of time — each required proof.
More than three years later, in September 2023, searchers found Suzanne’s remains near Moffat, Colorado, in the San Luis Valley. The case changed. What had once moved without a recovered body now had a new evidentiary center.
That center is not a weapon in the usual sense. It is a mixture known as BAM: butorphanol, azaperone, and medetomidine.
From a Missing Person Case to a Homicide Case
Barry Morphew was first arrested in May 2021 in connection with Suzanne’s presumed death. At that point, investigators had not recovered her remains. In April 2022, the original charges were dismissed without prejudice before trial. That phrase matters. It meant prosecutors could bring charges again later.
They did.
A grand jury indicted Barry Morphew in June 2025 on one count of first-degree murder in connection with Suzanne’s death. In January 2026, he pleaded not guilty. His trial is scheduled to begin October 13, 2026, and ABC News has reported it may last up to six weeks.
The language must stay precise. Prosecutors allege. The defense disputes. A jury has not yet heard the full case or reached a verdict.
Authorities later ruled Suzanne’s death a homicide by undetermined means, in the setting of butorphanol, azaperone, and medetomidine intoxication, according to reports. That wording is careful medical language. It does not say a single visible injury explains everything. It says the toxicology mattered to the conclusion.
What BAM Is — and Why Access Matters
BAM is not a household drug. The Colorado Sun reported that it is mainly used by wildlife biologists and veterinarians to sedate large animals under regulated access.
Each component has a role. Butorphanol is an opioid used in veterinary medicine. Azaperone is a tranquilizer that can calm stress responses. Medetomidine is a sedative that can slow the body down. Together, the mixture is designed for controlled immobilization, often in powerful animals where safety depends on restraint.
That restricted use is why access becomes evidence.
According to reporting on the indictment, prosecutors say only one private citizen in the Salida area had access to BAM: Barry Morphew. That allegation is significant, but it is not the same as proof of murder. Access opens a door. Prosecutors still have to connect that access to possession, administration, timing, and death.
A restricted drug can leave records: purchasing history, veterinary contacts, storage practices, training, disposal, missing material. It can also raise questions about knowledge. Who knew how to use it? Who could prepare it? Who had the opportunity?
Those questions will likely sit at the center of the Barry Morphew trial.
The Toxicology Fight Ahead
The defense position is direct. Defense attorney David Beller told The Colorado Sun that the claim Suzanne had BAM in her system is not true. In plain terms, the defense says the toxicology does not hold up.
That challenge matters because bone marrow toxicology is not like drawing blood from a living patient. Suzanne’s remains were found years after she disappeared. Time, soil, moisture, temperature, decomposition, and sample condition can all complicate chemical testing.
A detected compound does not automatically prove dose, timing, route, or intent. It means the next questions become more important.
Before jurors hear the chemistry, lawyers may fight over chain of custody: who handled the samples, where they were stored, how they moved, and whether the testing process was documented cleanly. They may also examine controls. A lab must show that a signal came from the sample itself, not equipment carryover, solvent contamination, or analyst error.
Modern forensic toxicology often uses mass spectrometry. In simple terms, the instrument separates molecules by weight and pattern, then compares them with known references. But the instrument does not interpret the case on its own. Analysts choose methods, thresholds, and conclusions. Those choices can become a trial inside the trial.
If prosecutors argue injection, they must support that route with evidence. With skeletal remains, a visible injection site may not be available. That makes the surrounding proof — access, preparation, timing, and behavior — more important.
What Jurors Will Have to Decide
This case may sound like a question about an unusual drug. It is narrower than that.
Jurors will not be asked whether BAM is rare. They will be asked whether the state proved its case beyond a reasonable doubt using evidence admitted in court.
Prosecutors may argue that three unusual compounds found together form a chemical fingerprint too specific to dismiss. The defense may argue that aged remains, difficult testing conditions, and disputed interpretation make the result unreliable. Both positions can sound plausible before the evidence is fully tested.
That is why reliability hearings before trial may be important. Judges decide what evidence can be presented. Jurors decide what weight to give it.
Suzanne Morphew was a person before she became the subject of a toxicology report. Her family waited years for the recovery of her remains. The delay changed the investigation, but it also deepened the human cost.
As the October 2026 trial approaches, watch three points: what the lab says it found, how that finding was validated, and how prosecutors connect it to Barry Morphew.
Until a verdict is reached, the honest answer remains limited. Suzanne is dead. Barry Morphew denies murder. The forensic toxicology fight is still ahead.
